1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
TCI GENE Inc.

TCI GENE Inc.

6879.TWO
TCI GENE Inc.TW flagTaipei Exchange
37.00
TWD
- -
- -
978.97MMarket Cap
TCI GENE Inc.
6879.TWO
(Taipei Exchange)

Recent

price

37.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
FRC
10.23
10.47
22.62
17.32
12.62
13.14
- -
Revenue per Share
3.07
1.94
4.84
2.95
0.44
2.13
- -
Basic EPS, GAAP
4.76
1.72
5.01
3.88
0.55
2.05
- -
Free Cash Flow per Basic Share
- -
- -
- -
2.19
2
1
- -
Dividend per Share
9.26
10.91
16.25
15.14
12.18
13.27
- -
Book Value per Share
9.12
11.24
20.14
41.4
37.97
37.54
- -
Tangible Book Value per Share
18
18
19
24
26
26
- -
Basic Weighted Avg Shares
189
193
432
424
334
348
274
Sales/Revenue/Turnover
29.83
24.13
26.28
21.48
1.8
16.05
6.97
Operating Margin (%)
6
7
38
30
16
14
12
Depreciation Expense
57
36
92
72
12
56
41
Net Income, GAAP
1.52
25.32
20.86
17.52
- -
16.33
- -
Effective Tax Rate (%)
30
18.53
21.39
17.01
3.5
16.2
14.83
Profit Margin (%)
139
160
317
933
913
893
816
Working Capital
- -
- -
- -
- -
- -
- -
- -
LT Debt
180
216
391
1,020
1,010
998
913
Total Equity
- -
17.1
27.68
10.24
- -
4.58
- -
Return on Invested Capital (%)
- -
18.37
34.68
19.69
- -
15.53
- -
Return on Capital (%)
- -
19.22
36.14
21.18
3.37
16.73
12.07
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
46.31%
-8.53%
Free Cash Flow
- -
112.87%
177.91%
Net Income, GAAP
- -
81.46%
-27.96%
Sales/Revenue/Turnover
- -
16.74%
-21.27%
Total Cash Common Dividend
- -
- -
100%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
334
2024
- -
- -
- -
- -
348
2025
- -
- -
- -
- -
274

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.44
2024
- -
- -
- -
- -
2.13
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
2
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
- -
Similar Companies
Genocea Biosciences, Inc. (GNCA)
eXoZymes, Inc. (EXOZ)
Actuate Therapeutics Inc (ACTU)
Mirxes Holding Company Limited (2629.HK)
Formycon AG (0W4N.L)
Agios Pharmaceuticals, Inc. (AGIO)
Business
TCI GENE Inc. (6879.TWO) provides precision preventive medicine solutions, including genetic testing and related health products, primarily in Taiwan. Founded in 2019 as a subsidiary of TCI Co., Ltd., the company is headquartered at No. 185 Gangchen Road, 10th Floor, Taipei, Taiwan, and listed on the Taipei Exchange in January 2022. It operates within the biotechnology and healthcare services sectors, targeting consumers seeking personalized health management through genetic insights and nutrition consultation services. The company offers genetic testing for nutrient metabolism and weight management; G2 and ACE2 genetic testing; supplements; skin care products; anti-aging solutions; kids' growth products; Alzheimer disease products; and serum tailored to DNA types. TCI GENE provides comprehensive precision medicine solutions encompassing preventive testing, disease treatment, and postoperative care, integrating genetic testing with cell therapy, tissue engineering, and human organ applications. Its services leverage advanced genetic technologies to assess individual constitutions and deliver customized health outcomes. In 2022, Qisda Corp. acquired a 17.84% stake in TCI GENE through a private placement valued at NT$545.16 million, forming a strategic alliance to expand biotechnology and precision medicine offerings by combining resources in genetic testing, medical services, equipment, and big data solutions. As part of the TCI Group, which evolved into a CDMO+ model in 2025 with AI-driven innovations for regulatory support and supply chain management, TCI GENE benefits from group-wide expansions including subsidiaries like TCI Living and MBI. The company maintains operations focused on Taiwan while supporting the group's presence across Asia, North America, and Europe.